Jan 5, 2026
Meet the partnership between Biofy and Oracle that uses AI and genetics to save lives quickly.
Biofy and Oracle: Revolutionizing the Fight Against Bacterial Resistance with Generative AI and OCI
Antimicrobial resistance is considered by the WHO to be one of the greatest threats to global public health. The average time for an accurate diagnosis via culture (the traditional antibiogram) is 5 to 7 days — an interval that critically ill patients often do not have. However, the partnership between Biofy and Oracle Cloud Infrastructure (OCI) is changing this reality, reducing the response time from days to less than 4 hours.
The recognition of this technology came through a global announcement from Oracle, highlighting how the Abby solution utilizes the most advanced AI to save lives.
The Technological Core: Abby + Oracle AI Vector Search
Biofy's differential lies not only in speed but also in the depth of analysis. While methods like PCR seek specific and limited targets, Abby performs Whole DNA Sequencing.
To process this massive amount of genetic data in record time, Biofy uses:
Oracle AI Vector Search: Allows mapping genetic materials against a database of over 720,000 bacterial genomes instantly.
OCI Generative AI: Large-scale language models (LLMs) that assist in interpreting resistance patterns, offering a personalized therapeutic recommendation for the doctor.
Real Impact: 75% More Agility in Diagnosis
By running on Oracle's infrastructure, Biofy achieved a performance 50% higher compared to other cloud providers, with reduced costs. This allows for the necessary scalability to serve hospitals and laboratories across Brazil.
Watch the official partnership video:
Why is the market looking at Biofy?
The Abby system addresses four critical pain points in modern hospital management:
Elimination of Culture: Direct extraction of DNA from blood, urine, saliva, or feces.
Total Identification: Identifies all present bacteria, not just the "suspected" ones.
Resistance Prediction (AMR): Detects resistance genes before the first dose of antibiotic.
Cost Efficiency: Reduces hospitalization time and the inappropriate use of high-cost reserve drugs.
The Future of Precision Medicine is Now
Biofy is not just creating software; it is building a new layer of intelligence for health. As highlighted by Oracle, the mission is to democratize access to advanced genomic diagnostics, ensuring that cutting-edge technology is available at the bedside.
Felipe Araújo